DDInter1756 DDInter1676
Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Telavancin {u} (Compound) resembles {v} (Compound) Oritavancin
Telavancin {u} (Compound) resembles {v} (Compound) Vancomycin
Telavancin {u} (Compound) is included by {v} (Pharmacologic Class) Lipoglycopeptides
Telavancin {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Telavancin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Telavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Castor oil
Telavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Telavancin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Telavancin {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Telavancin (Compound) resembles Oritavancin (Compound)
Telavancin (Compound) resembles Vancomycin (Compound)
Telavancin (Compound) is included by Lipoglycopeptides (Pharmacologic Class)
Telavancin (Compound) causes Abdominal discomfort (Side Effect)
Telavancin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Telavancin may lead to a major life threatening interaction when taken with Vemurafenib
Telavancin may lead to a major life threatening interaction when taken with Dolasetron